A new discovery about CO2 is challenging decades-old ventilation doctrine

Research kickstarted in the pandemic suggests that carbon dioxide makes it easier for viruses to stay alive in the air for longer.

June 4, 2024 Check out STAT+

Sponsored By

Today STAT reporters Olivia Goldhill and Meghana Keshavan have been tracking an FDA advisory panel on an MDMA therapy for PTSD. Read their updates in the live blog below. And don't miss the five takeaways from a special report by Lizzy Lawrence on how a device maker inundated pain patients with unwanted batteries and surprise bills.

Adobe A new discovery about carbon dioxide is challenging decades-old ventilation doctrine Research kickstarted in the pandemic suggests that carbon dioxide makes it easier for viruses to stay alive in the air for longer. By Megan Molteni STAT+ | Tracking the FDA advisory panel on MDMA therapy for PTSD FDA advisers weigh the first use of psychedelic therapy for post-traumatic stress disorder, review safety and efficacy data from MDMA trials. By Olivia Goldhill and Meghana Keshavan STAT+ | U.S. drug shortages have reached a decade high and are lasting longer, too "Economic pressures... have left our generic medicine supply chain fragile," said Anthony Lakavage of U.S. Pharmacopeia. By Ed Silverman Kayana Szymczak for STAT STAT+ | How a device maker inundated pain patients with unwanted batteries and surprise bills A $1,000 bill for batteries: Patients ordered Zynex Medical's TENS units to relieve pain. Now unwanted, uncovered batteries are hurting them. By Lizzy Lawrence STAT+ | Medicare Advantage plan's quality ratings were incorrectly calculated by government, judge rules A judge's ruling opens the door for Medicare Advantage plans to potentially recoup huge sums of taxpayer-funded bonuses. By Bob Herman Opinion: Outdated Medicare rules prevent some dementia patients from getting the medications they need Medicare has established policies that make it difficult for providers to prescribe appropriate antipsychotic drugs for dementia patients. By Carolyn Clevenger Molly Ferguson/STAT STAT+ | Novartis is flashing warning signs about the fate of its newly acquired myelofibrosis drug It's looking increasingly likely that the $3 billion purchase of MorphoSys to acquire pelabresib has run into serious trouble. By Adam Feuerstein

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser